2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines

2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer

2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer

2012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent

2012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent